Pharmaceuticals
Titan announces positive results from re-treatment study of probuphine
Titan Pharmaceuticals has announced the results of a six-month safety re-treatment study (PRO-811) of probuphine in patients with opioid dependence.
Categories: Pharmaceuticals
Tekmira wins US patent for LNP formulations, mitigation of immune stimulation
Tekmira Pharmaceuticals has received two US patents, one covering its lipid nanoparticle (LNP) delivery technology, and the other covering the chemical modification of siRNA to mitigate immune stimulation.
Categories: Pharmaceuticals
StayinFront expands services contract with biotechnology firm
StayinFront, a provider of CRM systems, has announced expanded agreement with a New Jersey-based global biotechnology firm to include a range of technical services to support its entire enterprise.
Categories: Pharmaceuticals
Sigma-Aldrich posts 15% rise in Q4 net profit
Sigma-Aldrich has reported a profit of $108m, or 89 cents a share, for the fourth quarter of 2011 compared to $94m, or 76 cents a share, for the same quarter of previous year.
Categories: Pharmaceuticals
AVI BioPharma reports data from AVI-6002, AVI-6003 trials
AVI BioPharma has reported the positive safety results from all six dose cohorts in the single ascending dose studies of its AVI-6002 and AVI-6003, being investigated for the treatment of Ebola virus and Marburg virus, respectively.
Categories: Pharmaceuticals
Rock Creek begins Anatabloc formulation trial
Rock Creek Pharmaceuticals has initiated second multi-site clinical trial to demonstrate the potential role for nutritional supplementation with its Anatabloc formulation in supporting immune health.
Categories: Pharmaceuticals
Genmab achieves second pre-clinical milestone in Lundbeck collaboration
Genmab has reached the second pre-clinical milestone in the collaboration with Lundbeck, triggering a €1m payment.
Categories: Pharmaceuticals
Branham investigates Pfizer for packaging error recall
Branham Law Group, a US law firm, is investigating Pfizer for its recall of 14 lots of Lo/Ovral-28 tablet packs and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets.
Categories: Pharmaceuticals
BioSante LibiGel study needs no modification, says DMC
BioSante Pharmaceuticals has announced that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study.
Categories: Pharmaceuticals
PPD forges research alliance with NRS
The Scottish government and Pharmaceutical Product Development (PPD) have formed an alliance to advance the development of new medical therapies and improve health care treatment options for the people of Scotland.
Categories: Pharmaceuticals
OptiNose enrolls first patient in Phase III intranasal technology trial
OptiNose has enrolled the first patient in a Phase III study involving the intranasal delivery of Sumatriptan powder using its bi-directional technology.
Categories: Pharmaceuticals
Catalyst files US provisional patent application for GABA aminotransferase inhibitors
Catalyst Pharmaceutical Partners has filed US provisional patent application for the use of GABA aminotransferase inhibitors, including CPP-109 and CPP-115, in the treatment of Tourette Syndrome.
Categories: Pharmaceuticals
Altheos begins patient dosing in glaucoma drug trial
Altheos has announced the dosing of first patient in a Phase 2a clinical trial of its lead investigational candidate, ATS907.
Categories: Pharmaceuticals
FDA clears Mobius glaucoma drug
The US Food and Drug Administration has granted final approval for Mobius Therapeutics' Mitosol, indicated for use in glaucoma surgery.
Categories: Pharmaceuticals
Forest, Gedeon report positive Phase III bipolar I disorder trial data
Forest Laboratories and Gedeon Richter have reported positive results from Phase III trial of cariprazine (RGH-188), an investigational antipsychotic agent, in patients with acute mania associated with bipolar I disorder.
Categories: Pharmaceuticals
Jubilant, Endo reach early stage milestones in research collaboration
Jubilant Biosys, a subsidiary of Jubilant Life Sciences, and Endo Pharmaceuticals have reached an early stage milestone in collaborative discovery program.
Categories: Pharmaceuticals
Takeda to open new development center in China
Takeda Pharmaceutical Company has announced the establishment of Takeda Shanghai Development Center (TSDC) within its wholly owned subsidiary, Takeda (China) Holdings (TCH).
Categories: Pharmaceuticals
Zalicus, Hydra to advance novel ion channel product candidates for pain therapy
Zalicus and Hydra Biosciences have signed an agreement to advance development of Zalicus’ preclinical ion channel modulator product candidates for the treatment of pain.
Categories: Pharmaceuticals
Mylan Doxycycline Hyclate tablets win FDA ANDA approval
Mylan Pharmaceuticals has received Abbreviated New Drug Application (ANDA) acceptance from the US Food and Drug Administration (FDA) for its Doxycycline Hyclate Delayed-release (DR) tablets USP, 150 mg.
Categories: Pharmaceuticals
Watson, Janssen settle ORTHO TRI-CYCLEN LO patent litigation
Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has reached a settlement with Janssen Pharmaceuticals over ORTHO TRI-CYCLEN LO norgestimate/ethinyl estradiol) patent litigation.
Categories: Pharmaceuticals
The Bottom Line:If Mr Cable has his way...
"If Mr Cable had his way, all the big banks would be broken up and bonuses would be virtually eliminated - a sure-fire way in my view of guaranteeing an end to the UK’s ability to compete as an international financial centre. Let’s not forget that this is a man who is on record as saying that everyone who works in a bank has an ‘aristocratic lifestyle’ clearly demonstrating his lack of understanding of the sector." A tough line on bankers’ bonuses could make a brain drain of financial talent a distinct possibility, warns Paul Marsden. Read more